本文测定了93例正常对照及16例多发性骨髓瘤(MM)患者的血β_2微球蛋白(β_2-m)含量,探讨了β_2-m与MM的分期、血红蛋白、体内肿瘤细胞数及生存期限的关系.并作了动态观察.结果表明:MM患者疗前β_2-m明显升高;疗前β_2-m与分期、体内肿瘤细胞数呈正相关,与Hb呈负相关.病程中可作为监视病情,预报复发的指标.疗前β_2-m高者,生存期短. In this study, β2-microglobulin (β_2-m) levels were measured in 93 normal controls and 16 patients with multiple myeloma (MM). The levels of β_2-m and MM, hemoglobin, tumor cell numbers and survival in vivo The results showed that: before treatment, β_2-m in MM patients was significantly increased; β_2-m before treatment was positively correlated with the number of tumor cells in vivo and negatively correlated with Hb, and could be used as a surveillance disease during the course of disease , Predict the recurrence of the index before treatment, β_2-m, short survival.